Antibody-mediated depletion of programmed death 1-positive (PD-1⁺) cells.

ABSTRACT: PD-1 immune checkpoint has been intensively investigated in pathogenesis and treatments for cancer and autoimmune diseases. Cells that express PD-1 (PD-1⁺ cells) draw ever-increasing attention in cancer and autoimmune disease research although the role of PD-1⁺ cells in the progression and treatments of these diseases remains largely ambiguous. One definite approach to elucidate their roles is to deplete these cells in disease settings and examine how the depletion impacts disease progression and treatments. To execute the depletion, we designed and generated the first depleting antibody (D-αPD-1) that specifically ablates PD-1⁺ cells. D-αPD-1 has the same variable domains as an anti-mouse PD-1 blocking antibody (RMP1-14). The constant domains of D-αPD-1 we

SUBMITTER: Zhai Y 

PROVIDER: S-EPMC10699550 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature